Approximately 90% of cancer patients with metastatic breast, prostate, lung or colon cancers develop resistance to chemotherapy. Despite scientific advances, cancer treatment failure due to treatment resistance is a major problem in oncology.
OncoGenex Pharmaceuticals Inc. (OGXI) has focused its efforts on the development of therapeutics that target important mechanisms of cancer treatment resistance with the potential to improve treatment outcomes for patients with a variety of cancers.
The company was established in May 2000 as a spin-out from the Prostate Centre at Vancouver General Hospital and the University of British Columbia. It was co-founded by urologist Martin Gleave, MD, and Scott Cormack, OncoGenex' President and CEO, initially to develop and commercialize custirsen (OGX-011), which was discovered at...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|